Does NIVOLUMAB Cause Hepatocellular carcinoma? 19 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 19 reports of Hepatocellular carcinoma have been filed in association with NIVOLUMAB (OPDIVO). This represents 0.0% of all adverse event reports for NIVOLUMAB.
19
Reports of Hepatocellular carcinoma with NIVOLUMAB
0.0%
of all NIVOLUMAB reports
6
Deaths
4
Hospitalizations
How Dangerous Is Hepatocellular carcinoma From NIVOLUMAB?
Of the 19 reports, 6 (31.6%) resulted in death, 4 (21.1%) required hospitalization.
Is Hepatocellular carcinoma Listed in the Official Label?
Yes, Hepatocellular carcinoma is listed as a known adverse reaction in the official FDA drug label for NIVOLUMAB.
What Other Side Effects Does NIVOLUMAB Cause?
Death (11,216)
Malignant neoplasm progression (9,363)
Off label use (5,208)
Diarrhoea (4,692)
Fatigue (3,709)
Pyrexia (3,454)
Intentional product use issue (3,297)
Rash (2,816)
Nausea (2,805)
Decreased appetite (2,619)
What Other Drugs Cause Hepatocellular carcinoma?
SORAFENIB (1,665)
RIBAVIRIN (1,046)
SOFOSBUVIR (877)
LEDIPASVIR\SOFOSBUVIR (640)
BEVACIZUMAB (532)
REGORAFENIB (470)
DACLATASVIR (419)
ATEZOLIZUMAB (342)
CABOZANTINIB S-MALATE (219)
TACROLIMUS (183)
Which NIVOLUMAB Alternatives Have Lower Hepatocellular carcinoma Risk?
NIVOLUMAB vs NIVOLUMAB\RELATLIMAB-RMBW
NIVOLUMAB vs NIZATIDINE
NIVOLUMAB vs NOMEGESTROL
NIVOLUMAB vs NORDAZEPAM
NIVOLUMAB vs NOREPINEPHRINE